Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) ...

European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease ...

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical ...

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in ...

Pfizer (PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...